Celldex Therapeutics

Celldex Therapeutics Inc (Nasdaq: CLDX) is a US-based clinical-stage biotech operating at the intersection of mast cell biology and targeted immunology. 

 The company is headquartered in Hampton, New Jersey and focuses on monoclonal and bispecific antibodies for allergic, inflammatory and autoimmune diseases.

Its lead programme, barzolvolimab, is a humanised monoclonal antibody that binds the KIT receptor on mast cells. The drug is being developed in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). A second programme, CDX-622, is a bispecific antibody targeting stem cell factor (SCF) and TSLP, under early clinical investigation. 

In its latest financial report, Celldex disclosed cash, cash equivalents and marketable securities of US$630 million as of 30 June 2025 and stated that this is sufficient to fund planned operations through about 2027. 

Leadership is headed by Anthony Marucci, Co-Founder, President and Chief Executive Officer. Celldex’s strategy is to leverage its mast cell-targeted science into multiple programmes with the potential to become first-in-class therapies in immune-mediated disease.